Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
- 286 Downloads
Zoledronate is a promising bisphosphonate that improves the bone mineral density by 0.69 standard deviations in thalassemia-induced osteoporosis, but the entire range of its actions and side effects is currently not fully understood.
Zoledronate is a promising bisphosphonate for the treatment of thalassemia-induced osteoporosis; however, a quantitative summary of its beneficial effect and its effects on the markers of bone turnover are not established.
We conducted a meta-analysis of the published randomized controlled trials using standardized mean difference and a random effects model for improvement in bone mineral density (BMD). We also conducted a systematic review for the influence of zoledronate on markers of bone turnover and bone pain.
We found that zoledronate improves the baseline BMD by 0.69 (95% confidence interval 0.47–0.90) standard deviations—an effect that was more pronounced when BMD was measured at the lumbar spine. However, the mechanistic interpretations of the effects on the markers of bone turnover are not completely clear.
Sufficient evidence exists to demonstrate that 4 mg zoledronate given every 3 months markedly improves the BMD; however, more qualitative and quantitative evidence is required to understand the mechanisms of its action and the potential side effects.
KeywordsOsteoclasts Thalassemia Zoledronate
Conflicts of interest
- 7.Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Shamshirsaz AA, Aghakhani S, Homayoun H, Larijani B (2003) Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 3:4CrossRefPubMedGoogle Scholar
- 19.Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91:1193–1202PubMedGoogle Scholar
- 21.Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590CrossRefPubMedGoogle Scholar
- 24.USFDA (2008) Information for Healthcare Professionals. http://www.fda.gov/cder/drug/InfoSheets/HCP/bisphosphonatesHCP.htm
- 25.USFDA (2008) Early Communication of an Ongoing Safety Review. http://www.fda.gov/cder/drug/early_comm/bisphosphonates.htm
- 27.Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 357:1799–1809 nihpa40967CrossRefPubMedGoogle Scholar
- 32.Patane S, Marte F (2008) Abnormal troponin I levels in a thalassemia major patient with high ferritin concentration, permanent atrial fibrillation and without acute coronary syndrome. Int J Cardiol doi: 10.1016/j.ijcard.2008.06.039